Lupu Jeremy, Hamann Pierre, Routier Émilie, Robert Caroline
Service de dermatologie, institut Gustave-Roussy, Villejuif, France.
Rev Prat. 2021 Apr;71(4):380-383.
Treatment of melanoma with immune checkpoints inhibitors .Immunotherapy with checkpoints inhibitors stimulates the anti-tumor response. It has dramatically changed the prognosis of advanced melanoma and other cancers. Anti-PD1, alone or in combination with anti-CTLA4, has demonstrated significantly better response and overall survival rates than chemotherapy. The immuno-mediated toxicity is more frequent and more serious with the combination of anti-PD1 and anti-CTLA4, which also appears as the most effective treatment for metastatic melanoma. Adjuvant anti-PD1 therapy is also effective in preventing recurrence in patients with resected stage III or IV melanoma. Studies are underway to evaluate this treatment in a neo-adjuvant situation and in localized melanomas with high risk of recurrence (stage II) with promising results.
用免疫检查点抑制剂治疗黑色素瘤。使用检查点抑制剂的免疫疗法可刺激抗肿瘤反应。它极大地改变了晚期黑色素瘤和其他癌症的预后。抗PD1单独使用或与抗CTLA4联合使用，已显示出比化疗显著更好的反应率和总生存率。抗PD1和抗CTLA4联合使用时，免疫介导的毒性更频繁、更严重，这也是转移性黑色素瘤最有效的治疗方法。辅助抗PD1治疗在预防III期或IV期黑色素瘤切除患者的复发方面也有效。正在进行研究以评估这种治疗在新辅助情况下以及在复发风险高的局限性黑色素瘤（II期）中的效果，结果很有前景。
